QSAR screening identifies antimalarial sesquiterpene lactones
QSAR virtual screening of a natural-product database prioritized compounds for in-vitro testing against chloroquine-sensitive and multidrug-resistant P. falciparum. The paper reports two sesquiterpene lactones, LDT-597 and LDT-598, with potent and selective activity. ADME/PBPK predictions are not measured pharmacokinetics, and the assays do not establish clinical efficacy.
Technology: QSAR activity models; QSPR ADME and PBPK predictors
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: Primary article reports experimental validation of two prioritized compounds against parasite strains and human hepatoma cells.
- Still unknown: Compound-level prior art and animal efficacy remain open; predicted PK is computational, not measured.
- AI role: QSAR screen prioritizes commercial natural products/derivatives for parasite and cytotoxicity assays.
Evidence sources: https://doi.org/10.3390/biom11030459
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 16 Nov 2026. Review scope: publisher primary full text. Material checked for the specific claims stated in the record..
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.